Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.
The pharmacokinetics and toxicity of two schedules of etoposide administration were studied in 19 patients suffering from metastatic non-small-cell lung cancer. Ten subjects received a 72-h continuous venous infusion (CVI) of 360 mg/m2 etoposide, and nine were given a daily dose of 120 mg/m2 for 3 consecutive days. In the two groups 80 mg/m2 cis-diamminedichloroplatinum (II) (CDDP) was infused on day 1. With CVI, the steady-state plasma concentration was reached 12-24 h after the start of the treatment. The plasma elimination rate showed a biexponential decay curve in both groups. No significant difference between total body clearance and the beta-phase volume of distribution was noted between the two modalities of administration. No relationship was found between biological and pharmacokinetic parameters.
Chatelut
E
E
Department de Biologie Clinique, Centre Claudius Regaud, Toulouse, France.
Chevreau
C
C
Blancy
E
E
Lequellec
A
A
Canal
P
P
Roche
H
H
Houin
G
G
Bugat
R
R
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012074:Remission Induction; D013921:Thrombocytopenia / Q000139:chemically induced
D005047:Etoposide; D002945:Cisplatin